Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the importantNovember 5, 2024 lead plaintiff deadline.
https://mma.prnewswire.com/media/405060/Rosen_Law_Logo.jpg
So what: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next:To join the Agenus class action, go to https://rosenlegal.com/submit-form/?case_id=28683or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination therapy of botensilimab, an antigen 4 blocking antibody that is in a Phase 2 clinical trial for the treatment of pancreatic cancer and melanoma, and balstilimab, an anti-PD-1 antagonist that has completed a Phase 2 clinical trial to treat second line cervical cancer, was less effective than defendants had led investors to believe; (2) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (3) as a result, Agenus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Agenus class action, go to https://rosenlegal.com/submit-form/?case_id=28683or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com
https://c212.net/c/img/favicon.png?sn=DC29504&sd=2024-10-13
View original content to download multimedia:https://www.prnewswire.com/news-releases/agen-investors-have-opportunity-to-lead-agenus-inc-securities-fraud-lawsuit-302274320.html
SOURCE THE ROSEN LAW FIRM, P. A.
https://rt.newswire.ca/rt.gif?NewsItemId=DC29504&Transmission_Id=202410130900PR_NEWS_USPR_____DC29504&DateId=20241013
COMTEX_458755190/1005/2024-10-13T09:00:30